TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03257176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures
Description: 21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
Study: NCT04375475

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bright Changyou probiotic flavored yogurt
Description: Oral consumption of Bright Changyou probiotic flavored yogurt 100 g at a time and twice per day for 28 days. The experimental product has similar package and taste as the comparators.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bright Changyou lactobacillus flavored yogurt
Description: Oral consumption of Bright Changyou lactobacillus flavored yogurt 100 g at a time and twice per day for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bright flavored yogurt
Description: Oral consumption of Bright flavored yogurt 100 g at a time and twice per day for 28 days.
Study: NCT02385188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: topical 5% imiquimod cream 3 times a week for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine in Vaseline ointment
Study: NCT01011023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non application of nasogastric tube in the experimental group
Description: Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non application of nasogastric tube in the experimental group
Description: Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
Study: NCT00723203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Day 1 and day 28 samples

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Day 1 and day 28 samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Day 1 and day 28 samples
Study: NCT00095680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCIO-469
Description: two 30-mg capsules three times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCIO-469 and bortezomib
Description: The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
Study: NCT03901118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chiauranib
Description: in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chiauranib
Description: in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
Study: NCT03104231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: three-dimensional (3D) movie
Description: Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
Study: NCT03175991

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: A morphologic evaluation will be performed according to International Ovarian Tumor Analysis Group recommendations for the following parameters:~Bilaterality , wall thickness, septations , papillary projections, solid areas, and echogenicity. The presence of ascites also will be recorded. Pattern recognition analysis will be used for ovarian masses highly suggestive of some diseases , then color Doppler will be activated to identify vascular color signals within the lesion.
Study: NCT00525694

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose tolerance test
Description: 10 ounces glucose tolerance test solution

Intervention type: OTHER
Group type: OTHER
Intervention: glucose tolerance test solution
Description: 75 grams glucose load

Intervention type: OTHER
Group type: OTHER
Intervention: Diet Coke
Description: 10 ounces of Diet Coke

Intervention type: OTHER
Group type: OTHER
Intervention: Coke Zero
Description: 10 ounces of Coke Zero
Study: NCT01222247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
Study: NCT03356860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 IV weekly from week 1 to week12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 IV weekly from week 1 to week12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2 IV Q 2 weeks from week 14 to week 20

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90 mg/m2 IV Q 2 weeks from week 14 to week 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV Q 2 weeks from week 14 to week 20

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV Q 2 weeks from week 14 to week 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV at week 14 and 18
Study: NCT03822624

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic mixture with three bacterial strains with maltodextrin as a carrier.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator with maltodextrin as a carrier.
Study: NCT01839825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuietCare
Study: NCT04391075

Intervention type: PROCEDURE
Intervention: Pudendal nerve block
Description: Pudendal nerve block provided during last fase of delivery
Study: NCT02451280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unilateral Hybrid Intervention
Description: For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Hybrid Intervention
Description: For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Training
Description: The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with bilateral protocols for 90 minutes. The tasks will be tailored according to the level
Study: NCT04055285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sympathetic Renal Denervation
Description: Catheter-based sympathetic renal denervation (RDN) using radiofrequency, ultrasound, or perivascular injection of neurotoxic agents such as alcohol has been introduced as a minimally invasive alternative treatment option for patients with resistant hypertension. RDN consists of endovascular catalysis of the kidney sympathetic nerves running in the wall of the renal arteries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Loop Recorder
Description: Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder
Description: Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
Study: NCT00877851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Program
Description: The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the computer-based program and some instructions on how to navigate around the different sections of the program. As a minimum level of use, participants will be asked to use the self-monitoring and goal setting aspects of the computer-based program on at least a weekly basis.
Study: NCT01861782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dead Sea Solar and Water Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur Pool & Medicinal Mud
Study: NCT02431533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PX0612
Description: PX0612 is a probiotic contained in a veggie capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Di-Calcium Phosphate
Description: Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
Study: NCT01400893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCD
Description: The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
Study: NCT02242461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rhodiola placebo capsules
Description: Corn starch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola Crenulata
Description: Rhodiola Crenulata
Study: NCT05498311

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy (IORT)
Description: The Intrabeam Photon Radiosurgery System will deliver 20 Gy in the act of breast surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast conservative surgery
Description: Breast conservative surgery with the aim of resecting breast tumour and with or without oncoplastic surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Hypofractionated Radiotherapy (EBRT)
Description: A External Beam Hypofractionated Radiotherapy will be administered after surgery. y. The dose per fraction will be 2.67 Gy per session. EBRT will be performed daily from Monday to Friday for fifteen fractions.
Study: NCT03956576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: [Pyr]apelin-13
Description: Peptide \[Pyr\]apelin-13 infusion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: [Pyr]apelin-13
Description: Peptide \[Pyr\]apelin-13 infusion
Study: NCT02031744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib [Tarceva]
Description: 150 mg oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg/kg intravenous administration every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab [MetMAb]
Description: 15 mg/kg intravenous administration every 3 weeks
Study: NCT02490384

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical exam indicated cerclage
Description: Cervical cerclage
Study: NCT03888365

Intervention type: DRUG
Intervention: Treprostinil
Description: Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.

Intervention type: DRUG
Intervention: Non-Treprostinil PAH Medications
Description: Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.
Study: NCT03083743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human Apo-2 ligand for Injection
Description: 150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
Study: NCT06160921

Intervention type: OTHER
Intervention: Standard therapy
Description: Individualized blood pressure reduction program
Study: NCT00935792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally
Study: NCT02956967

Intervention type: OTHER
Intervention: Overall satisfaction questionnaires of home use of Nivestim
Study: NCT02556723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of ziv-aflibercept
Description: All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
Study: NCT03585374

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methoxyflurane and Penthrox inhaler
Description: 3ml of methoxyflurane vaporized through an inhaler (Penthrox). Inhalation, by regular breathing, last about 25 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a dose of 0.10 mg/Kg body weight. The time of infusion should be not longer than 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 1 g dose The time of infusion should be not longer than 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen
Description: Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
Study: NCT02950662

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overdenture
Description: Active comparator will be metal housing and peek housing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overdenture
Description: Active comparator will be metal housing and peek housing
Study: NCT01208896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced_intensity conditioning
Description: The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
Study: NCT00510588

Intervention type: OTHER
Group type: OTHER
Intervention: training
Description: regular physical exercise training for 6 months

Intervention type: OTHER
Group type: OTHER
Intervention: training + metformin
Description: regular physical exercise training in combination with metformin for 6 months

Intervention type: OTHER
Group type: OTHER
Intervention: training + glitazon
Description: regular physical exercise training in combination with a glitazon for 6 months
Study: NCT03127241

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assistive device (Armon Ayura) test
Description: Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Assistive device (Jaeco Wrex) test
Description: Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported.
Study: NCT02441985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim RapidStim2
Description: Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Magstim RapidStim2
Description: Same procedure as real rTMS without stimulating the cerebral cortex.
Study: NCT03873129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile health app (mHealth)
Description: A-CHESS is a mobile health app for participants to interact with their treatment team for 12 months.
Study: NCT02188121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Angiotensin II receptor antagonist
Study: NCT02441985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fahn-Tolosa-Marin Tremor Rating Scale (TRS)
Description: All participants will receive a clinical assessment of tremor severity by using the TRS test.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Fahn-Tolosa-Marin Tremor Rating Scale (TRS)
Description: All participants will receive a clinical assessment of tremor severity by using the TRS test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timed Up & Go Test (TUG) test
Description: All participants will receive a clinical assessment of basic mobility skills by using the TUG test.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Timed Up & Go Test (TUG) test
Description: All participants will receive a clinical assessment of basic mobility skills by using the TUG test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10m walk test
Description: All participants will receive a clinical assessment of walking speed by using the walk test.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 10m walk test
Description: All participants will receive a clinical assessment of walking speed by using the walk test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tremor electrophysiology
Description: All participant tremors will by analyzed using an EMG system

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Tremor electrophysiology
Description: All participant tremors will by analyzed using an EMG system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebellar-brain Inhibition (CBI)
Description: All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cerebellar-brain Inhibition (CBI)
Description: All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
Study: NCT01984125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point-of-Care Prompt
Study: NCT01448174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:~* atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or~* placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks.
Study: NCT01682707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laryngoscopy
Description: tracheal intubation with two different techniques, track light and laryngoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: track light
Study: NCT01034761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pop-up alert
Description: Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
Study: NCT01155999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1225
Description: one drop twice daily (morning and evening) in each eye from Day 0 to Day 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: 1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6